Flajnik, M. F. & Kasahara, M. Foundation and evolution of the adaptive immune machine: genetic occasions and selective pressures. Nat. Rev. Genet. 11, 47–59 (2010).
Hirano, M. et al. Evolutionary implications of a 3rd lymphocyte lineage in lampreys. Nature 501, 435–438 (2013).
Lehner, P. J. The calculus of immunity: quantitating antigen processing. Immunity 18, 315–317 (2003).
Fehr, A. R. & Perlman, S. Coronaviruses: an summary in their replication and pathogenesis. Strategies Mol. Biol. 1282, 1–23 (2015).
Gorse, G. J., Patel, G. B., Vitale, J. N. & O’Connor, T. Z. Occurrence of antibodies to 4 human coronaviruses is decrease in nasal secretions than in serum. Clin. Vaccine Immunol. 17, 1875–1880 (2010).
Edridge, A. W. D. et al. Seasonal coronavirus protecting immunity is short-lasting. Nat. Med. 26, 1691–1693 (2020).
Saletti, G. et al. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Sci. Rep. 10, 21447 (2020).
Tang, F. et al. Loss of peripheral reminiscence B cellular responses in recovered sufferers with extreme acute respiration syndrome: a six-year follow-up find out about. J. Immunol. 186, 7264–7268 (2011).
Wu, L.-P. et al. Period of antibody responses after extreme acute respiration syndrome. Emerg. Infect. Dis. 13, 1562–1564 (2021).
Le Bert, N. et al. SARS-CoV-2-specific T cellular immunity in circumstances of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462 (2020).
Zhao, J. et al. Restoration from the Center East respiration syndrome is related to antibody and T-cell responses. Sci. Immunol. 2, eaan5393 (2017).
Mok, C. Ok. P. et al. T-cell responses to MERS coronavirus an infection in other folks with occupational publicity to dromedary camels in Nigeria: an observational cohort find out about. Lancet Infect. Dis. 21, 385–395 (2021).
Corridor, V. J. et al. SARS-CoV-2 an infection charges of antibody-positive when put next with antibody-negative health-care employees in England: a big, multicentre, potential cohort find out about (SIREN). Lancet 397, 1459–1469 (2021).
Murchu, E. O. et al. Quantifying the chance of SARS-CoV-2 reinfection through the years. Rev. Med. Virol. 32, e2260 (2022).
Liu, L. et al. Anti-spike IgG reasons extreme acute lung harm by means of skewing macrophage responses all the way through acute SARS-CoV an infection. JCI Perception 4, 123158 (2019).
Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir. Med. 8, e70 (2020).
Blanco-Melo, D. et al. Imbalanced host reaction to SARS-CoV-2 drives construction of COVID-19. Mobile 181, 1036–1045 (2020).
Hadjadj, J. et al. Impaired kind I interferon task and inflammatory responses in extreme COVID-19 sufferers. Science 369, 718–724 (2020).
Zhang, Q. et al. Inborn mistakes of kind I IFN immunity in sufferers with life-threatening COVID-19. Science 370, eabd4570 (2020).
Bastard, P. et al. Autoantibodies opposed to kind I IFNs in sufferers with life-threatening COVID-19. Science 370, eabd4585 (2020).
Lucas, C. et al. Longitudinal analyses disclose immunological misfiring in extreme COVID-19. Nature 584, 463–469 (2020).
Madden, E. A. & Diamond, M. S. Host cell-intrinsic innate immune popularity of SARS-CoV-2. Curr. Opin. Virol. 52, 30–38 (2021).
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and illness severity. Mobile 183, 996–1012 (2020).
Notarbartolo, S. et al. Built-in longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 sufferers. Sci. Immunol. 6, eabg5021 (2021).
Bergamaschi, L. et al. Longitudinal evaluation finds that behind schedule bystander CD8+ T cellular activation and early immune pathology distinguish extreme COVID-19 from gentle illness. Immunity 54, 1257–1275.e8 (2021).
Lucas, C. et al. Behind schedule manufacturing of neutralizing antibodies correlates with deadly COVID-19. Nat. Med. 27, 1178–1186 (2021).
Maurice, N. J., Taber, A. Ok. & Prlic, M. The unsightly duckling became to swan: a metamorphosis in belief of bystander-activated reminiscence CD8 T cells. J. Immunol. 206, 455–462 (2021).
RECOVERY Collaborative Team. Tocilizumab in sufferers admitted to medical institution with COVID-19 (RECOVERY): a randomised, managed, open-label, platform trial. Lancet 397, 1637–1645 (2021).
Chen, G. et al. Scientific and immunological options of extreme and reasonable coronavirus illness 2019. J. Clin. Make investments. 130, 2620–2629 (2020).
Laing, A. G. et al. A dynamic COVID-19 immune signature contains associations with deficient diagnosis. Nat. Med. 26, 1623–1635 (2020).
Kuri-Cervantes, L. et al. Complete mapping of immune perturbations related to extreme COVID-19. Sci. Immunol. 5, eabd7114 (2020).
Fox, A. et al. Critical pandemic H1N1 2009 an infection is related to temporary NK and T deficiency and aberrant CD8 responses. PLoS ONE 7, e31535 (2012).
Russell, C. D., Unger, S. A., Walton, M. & Schwarze, J. The human immune reaction to respiration syncytial virus an infection. Clin. Microbiol. Rev. 30, 481–502 (2017).
Diao, B. et al. Aid and useful exhaustion of T cells in sufferers with coronavirus illness 2019 (COVID-19). Entrance. Immunol. 11, 827 (2020).
Graham, M. B., Braciale, V. L. & Braciale, T. J. Influenza virus-specific CD4+ T helper kind 2 T lymphocytes don’t advertise restoration from experimental virus an infection. J. Exp. Med. 180, 1273–1282 (1994).
Su, Y. et al. Multi-omics resolves a pointy disease-state shift between gentle and reasonable COVID-19. Mobile 183, 1479–1495 (2020).
Mathew, D. et al. Deep immune profiling of COVID-19 sufferers finds distinct immunotypes with healing implications. Science 369, eabc8511 (2020).
Rha, M.-S. et al. PD-1-expressing SARS-CoV-2-specific CD8+ T cells don’t seem to be exhausted, however useful in sufferers with COVID-19. Immunity 54, 44–52 (2021).
Shen-Orr, S. S. et al. Faulty signaling within the JAK–STAT pathway tracks with continual irritation and cardiovascular chance in getting older people. Mobile Syst. 3, 374–384 (2016).
Yu, Ok. Ok. et al. Comorbid diseases are related to altered adaptive immune responses to SARS-CoV-2. JCI Perception 6, 146242 (2021).
Le Bert, N. et al. Extremely useful virus-specific mobile immune reaction in asymptomatic SARS-CoV-2 an infection. J. Exp. Med. 218, e20202617 (2021).
Grau-Expósito, J. et al. Peripheral and lung resident reminiscence T cellular responses opposed to SARS-CoV-2. Nat. Commun. 12, 3010 (2021).
Gao, M. et al. Regulatory CD4+ and CD8+ T cells are negatively correlated with CD4+/CD8+ T cellular ratios in sufferers acutely contaminated with SARS-CoV-2. J. Leukoc. Biol. 109, 91–97 (2021).
Hillaire, M. L. B., Rimmelzwaan, G. F. & Kreijtz, J. H. C. M. Clearance of influenza virus infections by means of T cells: chance of collateral harm? Curr. Opin. Virol. 3, 430–437 (2013).
Track, J.-W. et al. Immunological and inflammatory profiles in gentle and extreme circumstances of COVID-19. Nat. Commun. 11, 3410 (2020).
Schaller, T. et al. Postmortem exam of sufferers with COVID-19. J. Am. Med. Assoc. 323, 2518–2520 (2020).
Deinhardt-Emmer, S. et al. Early postmortem mapping of SARS-CoV-2 RNA in sufferers with COVID-19 and the correlation with tissue harm. eLife 10, e60361 (2021).
RECOVERY Collaborative Team. Dexamethasone in hospitalized sufferers with COVID-19. N. Engl. J. Med. 384, 693–704 (2021).
RECOVERY Collaborative Team. Tocilizumab in sufferers admitted to medical institution with COVID-19 (RECOVERY): a randomised, managed, open-label, platform trial. Lancet 397, 1637–1645 (2021).
Peng, Y. et al. Wide and powerful reminiscence CD4+ and CD8+ T cells brought on by means of SARS-CoV-2 in UK convalescent COVID-19 sufferers. Nat. Immunol. 21, 1336–1345 (2020).
Tarke, A. et al. Complete evaluation of T cellular immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 circumstances. Mobile Rep. Med. 2, 100204 (2021).
Grifoni, A. et al. Goals of T cellular responses to SARS-CoV-2 coronavirus in people with COVID-19 illness and unexposed folks. Mobile 181, 1489–1501 (2020).
Juno, J. A. et al. Humoral and circulating follicular helper T cellular responses in recovered sufferers with COVID-19. Nat. Med. 26, 1428–1434 (2020).
Boppana, S. et al. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and build up all the way through early convalescence. PLoS Pathog. 17, e1009761 (2021).
Stephenson, E. et al. Unmarried-cell multi-omics evaluation of the immune reaction in COVID-19. Nat. Med. 27, 904–916 (2021).
Grifoni, A. et al. SARS-CoV-2 human T cellular epitopes: adaptive immune reaction opposed to COVID-19. Mobile Host Microbe 29, 1076–1092 (2021).
Quadeer, A. A., Ahmed, S. F. & McKay, M. R. Panorama of epitopes centered by means of T cells in 852 folks recovered from COVID-19: meta-analysis, immunoprevalence, and internet platform. Mobile Rep. Med. 2, 100312 (2021).
Verhagen, J. et al. Human CD4+ T cells particular for dominant epitopes of SARS-CoV-2 spike and nucleocapsid proteins with healing attainable. Clin. Exp. Immunol. 205, 363–378 (2021).
Low, J. S. et al. Clonal evaluation of immunodominance and cross-reactivity of the CD4 T cellular reaction to SARS-CoV-2. Science 372, 1336–1341 (2021).
Weingarten-Gabbay, S. et al. Profiling SARS-CoV-2 HLA-I peptidome finds T cellular epitopes from out-of-frame ORFs. Mobile 184, 3962–3980 (2021).
Nagler, A. et al. Identity of offered SARS-CoV-2 HLA elegance I and HLA elegance II peptides the use of HLA peptidomics. Mobile Rep. 35, 109305 (2021).
Peng, Y. et al. An immunodominant NP105-113-B*07:02 cytotoxic T cellular reaction controls viral replication and is related to much less extreme COVID-19 illness. Nat. Immunol. 23, 50–61 (2022).
Cohen, Ok. W. et al. Longitudinal evaluation displays sturdy and extensive immune reminiscence after SARS-CoV-2 an infection with persisting antibody responses and reminiscence B and T cells. Mobile Rep. Med. 2, 100354 (2021).
Bieberich, F. et al. A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes finds age-related variations in convalescent COVID-19 sufferers. Entrance. Immunol. 12, 701085 (2021).
Bilich, T. et al. T cellular and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent folks. Sci. Transl. Med. 13, eabf7517 (2021).
Yang, J.-R. et al. Power viral RNA positivity all the way through the restoration length of a affected person with SARS-CoV-2 an infection. J. Med. Virol. 92, 1681–1683 (2020).
Jung, J. H. et al. SARS-CoV-2-specific T cellular reminiscence is continued in COVID-19 convalescent sufferers for 10 months with a hit construction of stem cell-like reminiscence T cells. Nat. Commun. 12, 4043 (2021).
Wheatley, A. Ok. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).
Zuo, J. et al. Tough SARS-CoV-2-specific T cellular immunity is maintained at 6 months following number one an infection. Nat. Immunol. 22, 620–626 (2021).
Adamo, S. et al. Signature of long-lived reminiscence CD8+ T cells in acute SARS-CoV-2 an infection. Nature https://doi.org/10.1038/s41586-021-04280-x (2021).
Szabo, P. A. et al. Longitudinal profiling of respiration and systemic immune responses finds myeloid cell-driven lung irritation in extreme COVID-19. Immunity 54, 797–814 (2021).
Routhu, N. Ok. et al. A changed vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 an infection, immune pathology, and disorder within the lungs. Immunity 54, 542–556 (2021).
Stoddard, C. I. et al. Epitope profiling finds binding signatures of SARS-CoV-2 immune reaction in herbal an infection and cross-reactivity with endemic human CoVs. Mobile Rep. 35, 109164 (2021).
Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat. Rev. Immunol. 20, 457–458 (2020).
Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 sufferers with acute respiration misery syndrome. Sci. Immunol. 5, eabd2071 (2020).
Ogbe, A. et al. T cellular assays differentiate scientific and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat. Commun. 12, 2055 (2021).
Lineburg, Ok. E. et al. CD8+ T cells particular for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity 54, 1055–1065 (2021).
Yewdell, J. W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cellular responses. Immunity 25, 533–543 (2006).
Ng, Ok. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in people. Science 7, 1339–1343 (2020).
Dowell, A. C. et al. Kids increase powerful and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 an infection. Nat. Immunol. 23, 40–49 (2022).
Meade, P. et al. Influenza virus an infection induces a slender antibody reaction in youngsters however a extensive recall reaction in adults. mBio 11, e03243-19 (2020).
Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune reaction to respiration coronaviruses. Immunol. Res. 59, 118–128 (2014).
Zhao, J., Zhao, J. & Perlman, S. T cellular responses are required for defense from scientific illness and for virus clearance in extreme acute respiration syndrome coronavirus-infected mice. J. Virol. 84, 9318–9325 (2010).
Sagar, M. et al. Fresh endemic coronavirus an infection is related to less-severe COVID-19. J. Clin. Make investments. 131, 143380 (2021).
Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with illness coverage opposed to influenza problem in people. Nat. Med. 18, 274–280 (2012).
Sridhar, S. et al. Mobile immune correlates of coverage opposed to symptomatic pandemic influenza. Nat. Med. 19, 1305–1312 (2013).
Nguyen, T. H. O. et al. CD8+ T cells particular for an immunodominant SARS-CoV-2 nucleocapsid epitope show top naive precursor frequency and TCR promiscuity. Immunity 54, 1066–1082 (2021).
Bacher, P. et al. Low-avidity CD4+ T cellular responses to SARS-CoV-2 in unexposed folks and people with extreme COVID-19. Immunity 53, 1258–1271 (2020).
Dykema, A. G. et al. Purposeful characterization of CD4+ T cellular receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J. Clin. Make investments. 131, 146922 (2021).
Robson, F. et al. Coronavirus RNA proofreading: molecular foundation and healing focused on. Mol. Mobile 79, 710–727 (2020).
Fischer, W. et al. HIV-1 and SARS-CoV-2: patterns within the evolution of 2 pandemic pathogens. Mobile Host Microbe 29, 1093–1110 (2021).
Liu, C. et al. Lowered neutralization of SARS-CoV-2 B.1.617 by means of vaccine and convalescent serum. Mobile 184, 4220–4236 (2021).
Woldemeskel, B. A., Garliss, C. C. & Blankson, J. N. SARS-CoV-2 mRNA vaccines induce extensive CD4+ T cellular responses that acknowledge SARS-CoV-2 variants and HCoV-NL63. J. Clin. Make investments. 131, 149335 (2021).
Redd, A. D. et al. CD8+ T-cell responses in COVID-19 convalescent folks goal conserved epitopes from more than one distinguished SARS-CoV-2 circulating variants. Open Discussion board Infect. Dis. 8, ofab143 (2021).
Tarke, A. et al. Have an effect on of SARS-CoV-2 variants at the overall CD4+ and CD8+ T cellular reactivity in contaminated or vaccinated folks. Mobile Rep. Med. 2, 100355 (2021).
de Silva, T. I. et al. The affect of viral mutations on popularity by means of SARS-CoV-2 particular T-cells. iScience 24, 103353 (2021).
Woolthuis, R. G., van Dorp, C. H., Keşmir, C., de Boer, R. J. & van Boven, M. Lengthy-term adaptation of the influenza An endemic by means of escaping cytotoxic T-cell popularity. Sci. Rep. 6, 33334 (2016).
Zhang, Y. et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion via down-regulating MHC-Ι. Proc. Natl Acad. Sci. USA 118, e2024202118 (2021).
McMahan, Ok. et al. Correlates of coverage opposed to SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
Zhao, J. et al. Airway reminiscence CD4+ T cells mediate protecting immunity opposed to rising respiration coronaviruses. Immunity 44, 1379–1391 (2016).
Sekine, T. et al. Tough T cellular immunity in convalescent folks with asymptomatic or gentle COVID-19. Mobile 183, 158–168 (2020).
Nelde, A. et al. SARS-CoV-2-derived peptides outline heterologous and COVID-19-induced T cellular popularity. Nat. Immunol. 22, 74–85 (2021).
da Silva Antunes, R. et al. Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in neighborhood and fitness care employees. J. Infect. Dis. 224, 70–80 (2021).
Rowland-Jones, S. L. & McMichael, A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7, 448–455 (1995).
Swadling, L. et al. Pre-existing polymerase-specific T cells amplify in abortive seronegative SARS-CoV-2. Nature 601,110–117 (2022).
Zeng, C. et al. SARS-CoV-2 spreads via cell-to-cell transmission. Proc. Natl Acad. Sci. USA 119, e2111400119 (2022).
Igakura, T. et al. Unfold of HTLV-I between lymphocytes by means of virus-induced polarization of the cytoskeleton. Science 299, 1713–1716 (2003).
Cohen, B. et al. COVID-19 an infection in 10 not unusual variable immunodeficiency sufferers in New York Town. J. Allergic reaction Clin. Immunol. Pract. 9, 504–507 (2021).
Bange, E. M. et al. CD8+ T cells give a contribution to survival in COVID-19 sufferers with hematologic cancers. Nat. Med. 27, 1280–1289 (2021).
Pfizer. Pfizer and BioNTech announce vaccine candidate opposed to COVID-19 completed luck in first period in-between evaluation from section 3 find out about. https://www.pfizer.com/information/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against (2020).
Tregoning, J. S., Flight, Ok. E., Higham, S. L., Wang, Z. & Pierce, B. F. Growth of the COVID-19 vaccine effort: viruses, vaccines and variants as opposed to efficacy, effectiveness and break out. Nat. Rev. Immunol. 21, 626–636 (2021).
Oberhardt, V. et al. Fast and strong mobilization of CD8+ T cells by means of SARS-CoV-2 mRNA vaccine. Nature 597, 268–273 (2021).
Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in people. Nature 595, 572–577 (2021).
Skelly, D. T. et al. Two doses of SARS-CoV-2 vaccination induce powerful immune responses to rising SARS-CoV-2 variants of outrage. Nat. Commun. 12, 5061 (2021).
Parry, H. et al. Immunogenicity of unmarried vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks submit vaccine in contributors elderly 80 years or older: an exploratory evaluation. Lancet Wholesome Longev. 2, e554–e560 (2021).
Parry, H. et al. Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous twin vaccination in older other folks. Immun. Getting older A 18, 34 (2021).
Stuart, A. S. V. et al. Immunogenicity, protection, and reactogenicity of heterologous COVID-19 number one vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the United Kingdom (Com-COV2): a single-blind, randomised, section 2, non-inferiority trial. Lancet 399, 36–49 (2022).
Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature 600, 701–706 (2021).
Shaw, R. H. et al. Heterologous prime-boost COVID-19 vaccination: preliminary reactogenicity knowledge. Lancet 397, 2043–2046 (2021).
Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cellular immunity. Nature https://doi.org/10.1038/s41586-021-04232-5 (2021).
Mazzoni, A. et al. First-dose mRNA vaccination is enough to reactivate immunological reminiscence to SARS-CoV-2 in topics who’ve recovered from COVID-19. J. Clin. Make investments. 131, 149150 (2021).
Folegatti, P. M. et al. Protection and immunogenicity of the ChAdOx1 nCoV-19 vaccine opposed to SARS-CoV-2: a initial file of a section 1/2, single-blind, randomised managed trial. Lancet 396, 467–478 (2020).
Rice, A. et al. Intranasal plus subcutaneous top vaccination with a twin antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Sci. Rep. 11, 14917 (2021).
Cromer, D. et al. Possibilities for sturdy immune keep an eye on of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395–404 (2021).
Earle, Ok. A. et al. Proof for antibody as a protecting correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).
Khoury, D. S. et al. Neutralizing antibody ranges are extremely predictive of immune coverage from symptomatic SARS-CoV-2 an infection. Nat. Med. 27, 1205–1211 (2021).
Nathan, A. et al. Construction-guided T cellular vaccine design for SARS-CoV-2 variants and sarbecoviruses. Mobile 184, 4401–4413 (2021).
Shoukat, M. S. et al. Use of system finding out to spot a T cellular reaction to SARS-CoV-2. Mobile Rep. Med. 2, 100192 (2021).
Singer, J., Gifford, R., Cotten, M. & Robertson, D. L. CoV-GLUE; http://cov-glue.cvr.gla.ac.united kingdom/#/house
Shu, Y. & McCauley, J. GISAID: world initiative on sharing all influenza knowledge — from imaginative and prescient to truth. Eur. Surveill. 22, 30494 (2017).
Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein constructions tell on virus evolution and furin-cleavage results. Nat. Struct. Mol. Biol. 27, 763–767 (2020).